Role of PCGEM1 in Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No Biologics.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Long Non-coding RNA: PCGEM1 as a Potential Marker for Tumorigenesis in Breast Cancer
Overview
This study examines certain molecular markers in breast cancer using blood and tissue samples from routine diagnostic biopsies. No extra procedures will be performed on patients. The goal is to improve understanding of disease mechanisms and identify potential targets for treatment
Detailed description
This is an observational, case-control study designed to evaluate the expression of lncRNA PCGEM1 and its association with related molecular pathways, including RhoA, TRIAP1, and ferroptosis, in breast cancer patients. The study will include patients diagnosed with breast cancer and a matched control group.
No intervention will be performed as part of this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care, with no additional procedures carried out for research purposes.
Collected tissue samples will be processed for RNA extraction and subsequent molecular analysis to assess gene expression levels. The results will be analyzed to explore the potential role of PCGEM1 in tumor progression and its correlation with selected molecular pathways.
The findings of this study may contribute to a better understanding of breast cancer biology and help identify potential biomarkers or therapeutic targets.
Interventions
- Device No Biologics
No intervention will be performed in this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care
Primary outcome measures
- Relative expression level of PCGEM1 marker in breast cancer tissue and blood sample [Time frame: at base line]
Eligibility criteria
Inclusion criteria
- Age: 18 years and older.
- Newly diagnosed patients with histopathological confirmation of the diagnosis of breast cancer at any stage.
Exclusion criteria
- Presence of any chronic diseases.
- Previous history of breast cancer or other malignancies.
- Evidence of distant metastasis at the time of diagnosis.
- Prior treatment with chemotherapy or radiotherapy.
- Incomplete clinical or laboratory data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Kumar S, Prajapati KS, Singh AK, Kushwaha PP, Shuaib M, Gupta S. Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer. Cancer Lett. 2021 Apr 28;504:15-22. doi: 10.1016/j.canlet.2020.11.039. Epub 2021 Feb 6. PMID 33556545
Identifiers
NCT: NCT07562789 · Breast cancer and PCGEM1